Big deals in Chinese big-pharma as BeiGene raises another $2 billion, Biogen and Moderna both release papers on crucial clinical trials, and a new cell-type could play a pivotal role in rheumatoid arthritis.

Biogen has submitted their Alzheimer’s drug aducanumab to the FDA, we take a look at the fate of PPD since their February IPO, and explore Gilead’s not-a-claim claims on their COVID-19 treatment.

Two deaths in a gene therapy trial, new COVID-19 vaccine guidelines from the FDA, and recent developments in CRISPR-Cas gene editing technologies.